Thank you very much for the question.
I think there are a lot of different issues that come out of this particular discussion, but if I can, I'll address the number of concerns. When you think about the need for developing countries in relation to access to medicines, I don't think we are here talking about primarily access to patented medicines. I think if you have a look at the research done on the ground, access to any medicines is a problem in any of these places. I attended a presentation in Geneva by the World Health Organization that highlighted that poverty remains a significant problem. If you cannot afford to buy the cheapest generic, buying generic or patented medicines is particularly problematic. The other problem they mentioned specifically in relation to this problem is access to clean water.
So all of these things feed into the general health and well-being of the individual people. The call, as has been mentioned significantly, is that governments really do need to pay attention as to how much money they are putting into their health budgets. If governments are not willing to put in sufficient amounts to guarantee access to the most simple non-patented generics, then it would be a very significant challenge for them to get access to generics of patented versions of medicines, because these are not cheap medicines, by and large. They still have some costs. They are cheaper, but there is a cost associated with that.
That is why I think it is important for us to think about the generic access to medicines debate rather than simply looking at a very small subset of the tools available. Compulsory licensing has been proven in some countries to be a short-term fix. It's not seen by many as being a sustainable solution to the access to medicines problem and access to medicines debate. I mean, I can submit for you for the record the massive expansion of our industry efforts in relation to access to medicines. I think I've submitted a short statement on that, but I can give you a little bit more detail on the rapid expansion of the effort that our companies are putting into achieving access to medicines. Simply—